KZIA Stock News Today: Kazia Therapeutics Soars on Rare Cancer Response as Nasdaq Delisting Risk Looms
Kazia Therapeutics Limited is back on traders’ radars today after unveiling a rare immune‑complete response in a patient with metastatic triple‑negative breast cancer – even as the micro‑cap oncology company discloses a fresh Nasdaq delisting warning and files a new prospectus supplement with the U.S. SEC. Nasdaq+2Investing.com Australia+2 The core of today’s excitement is an update on a single, heavily pre‑treated patient with stage IV triple‑negative breast cancer, one of the most aggressive and difficult‑to‑treat breast‑cancer subtypes.